Dietary α-Linolenic Acid-Rich Flaxseed Oil Exerts Beneficial Effects on Polycystic Ovary Syndrome Through Sex Steroid Hormones—Microbiota—Inflammation Axis in Rats

Ting Wang¹, Liping Sha²†, Yiwei Li¹, Lili Zhu¹, Zhen Wang², Ke Li³, Haixia Lu³, Ting Bao², Li Guo⁵, Xiaoxia Zhang⁶* and Hao Wang¹*

¹Department of Pathogenic Biology and Medical Immunology, School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, China, ²Endocrinology Department, General Hospital of Ningxia Medical University, Yinchuan, China, ³People’s Hospital of Ningxia Hui Autonomous Region, Yinchuan, China, ⁴Clinical Medical College, Ningxia Medical University, Yinchuan, China, ⁵Department of Anatomy and Histology, School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, China, ⁶College of Traditional Chinese Medicine, Ningxia Medical University, Yinchuan, China

Polycystic ovary syndrome (PCOS) represents a common endocrine—metabolic disorder disease with chronic low-grade inflammation and alteration of intestinal flora. Served as functional food, flaxseed oil (FO), which is rich in plant-derived α-linolenic acid of omega-3 polyunsaturated fatty acids, has been proven to benefit for chronic metabolic diseases. However, the exact role of dietary FO on PCOS remains largely unclear. In the present study, 6-week-old female Sprague–Dawley rats were randomly divided into four groups (eight rats/group), including (a) pair-fed (PF) control (CON) group (PF/CON), (b) FO-fed CON group (FO/CON), (c) PF with letrozole-induced PCOS model (MOD) group (PF/MOD), and (d) FO-fed MOD group (FO/MOD). All rats were fed a standard diet. After 3 weeks of modeling and subsequent 8 weeks of treatment, the rats in diverse groups were euthanized and associated indications were investigated. The results showed that dietary FO ameliorated the disorder of estrous cycle and ovarian morphology. In parallel, dietary FO improved the sex steroid hormone disturbance (luteinizing hormone/follicle-stimulating hormone, estrogen, testosterone, and progesterone), body weights, dyslipidemia, and insulin resistance. Moreover, FO treatment improved plasma and ovary inflammatory interleukin (IL)-1β, IL-6, IL-10, and IL-17A, tumor necrosis factor-α, and monocyte chemoattractant protein-1. Additionally, FO intervention significantly modulated the composition of gut microbiota and vaginal microbiota by increasing the abundances of Allobaculum, Lactobacillus, Bifidobacterium, Desulfovibrio, Bifidobacterium, Faecalibacterium, Parabacteroides as well as decreasing the abundances of Actinobacteria, Bacteroides, Proteobacteria, and Streptococcus, the ratio of Firmicutes/Bacteroidetes. A decrease in plasma lipopolysaccharide level and an increase in short-chain fatty acids, including acetic acid, propionic acid, butyric acid and pentanoic acid, were determined after dietary FO supplementation. Correlation analysis...
revealed close relationships among sex steroid hormones, inflammation, and gut/vaginal microbiota. Collectively, this study demonstrated that dietary FO ameliorated PCOS through the sex steroid hormones—microbiota—inflammation axis in rats, which may contribute to the understanding of pathogenesis and potentially serve as an inexpensive intervention in the control of PCOS.

**Keywords:** FO, PCOS, sex steroid hormones, inflammation, gut microbiota, VMB

**INTRODUCTION**

Polycystic ovary syndrome (PCOS) represents a common endocrine—metabolic disorder among women of reproductive ages, with a worldwide prevalence of 4–21% (1). Patients with PCOS largely present metabolic and other clinical features including hyperandrogenemia, hyperinsulinemia, obesity, dyslipidemia, insulin resistance, ovulatory dysfunction, menstrual irregularity, and polycystic ovaries (2–4). Moreover, PCOS may cause an increased risk of metabolic disorders, such as type 2 diabetes mellitus (T2DM), cardiovascular disease, metabolic syndrome, endometrial cancer, infertility, obstetrical complications, psychiatric conditions, and other complications (5–7). Recently, genetic, lifestyle, and environmental triggers have been considered as the main drivers of PCOS (8–11), but the exact pathogenesis remains largely unclear. In view of the limitations of current therapeutics for the metabolic symptoms of PCOS, novel and more practical strategies for the control of PCOS are needed.

Numerous evidences have demonstrated that abnormal sex steroid hormones are crucial parameters in PCOS manifestation and development (12). One of the core pathophysiologic features of PCOS is hyperandrogenism, which is caused by elevated testosterone (T) (13). Testosterone levels are increased in the presence of tumor necrosis factor (TNF)-α (14). Moreover, PCOS may cause an increased risk of metabolic disorders, such as type 2 diabetes mellitus (T2DM), cardiovascular disease, metabolic syndrome, endometrial cancer, infertility, obstetrical complications, psychiatric conditions, and other complications (5–7). Recently, genetic, lifestyle, and environmental triggers have been considered as the main drivers of PCOS (8–11), but the exact pathogenesis remains largely unclear. In view of the limitations of current therapeutics for the metabolic symptoms of PCOS, novel and more practical strategies for the control of PCOS are needed.

Numerous evidences have demonstrated that abnormal sex steroid hormones are crucial parameters in PCOS manifestation and development (12). One of the core pathophysiologic features of PCOS is hyperandrogenism, which is caused by elevated testosterone (T) (13). Testosterone levels are increased in the presence of tumor necrosis factor (TNF)-α (14). Moreover, PCOS may cause an increased risk of metabolic disorders, such as type 2 diabetes mellitus (T2DM), cardiovascular disease, metabolic syndrome, endometrial cancer, infertility, obstetrical complications, psychiatric conditions, and other complications (5–7). Recently, genetic, lifestyle, and environmental triggers have been considered as the main drivers of PCOS (8–11), but the exact pathogenesis remains largely unclear. In view of the limitations of current therapeutics for the metabolic symptoms of PCOS, novel and more practical strategies for the control of PCOS are needed.

Numerous evidences have demonstrated that abnormal sex steroid hormones are crucial parameters in PCOS manifestation and development (12). One of the core pathophysiologic features of PCOS is hyperandrogenism, which is caused by elevated testosterone (T) (13). Testosterone levels are increased in the presence of tumor necrosis factor (TNF)-α (14). Moreover, PCOS may cause an increased risk of metabolic disorders, such as type 2 diabetes mellitus (T2DM), cardiovascular disease, metabolic syndrome, endometrial cancer, infertility, obstetrical complications, psychiatric conditions, and other complications (5–7). Recently, genetic, lifestyle, and environmental triggers have been considered as the main drivers of PCOS (8–11), but the exact pathogenesis remains largely unclear. In view of the limitations of current therapeutics for the metabolic symptoms of PCOS, novel and more practical strategies for the control of PCOS are needed.
Wang et al. FO Ameliorates PCOS in Rats

FIGURE 1 | Schematic time diagram of the experimental design.

MATERIALS AND METHODS

Animals and Diet
Six-week-old specific-pathogen-free female Sprague–Dawley (SD) rats (body weight, 193 ± 10 g) were purchased from the Laboratory Animal Center of Ningxia Medical University. All animal experiments were approved by the Ethics Committee of Ningxia Medical University (No. 2016-017). The animals were acclimatized for 1 week in polycarbonate cages at a temperature-controlled room (22 ± 2°C, air humidity 40–70%) under a 12-h light and dark cycle.

All animals were fed with a commercial diet of Keaoxieli Feed Co., Ltd., Beijing, China (46.65% crude protein, 20.73% moisture, 0.09% crude fat, 0.13% crude ash, 0.07% crude fiber, microelement calcium, and phosphorus). FO was purchased from Liupanzhen Square Ecological Agricultural Science and Technology Co., Ltd., Ningxia, China, the fatty acid composition of which was identified by gas chromatography–mass spectrometry (GC-MS) (Table S1). Letrozole was obtained from Hengrui Pharmaceutical Co., Ltd., Jiangsu, China.

Experimental Design
The schematic time diagram of the experimental design is shown in Figure 1. In brief, after a 1-week period of acclimation with the control diet, 32 female SD rats (6 weeks old) were randomly assigned into four groups (eight rats/group): (a) pair-fed (PF) control (CON) group (PF/CON), (b) FO-fed CON group (FO/CON), (c) PF with letrozole-induced PCOS model (MOD) group (PF/MOD), and (d) PF with FO-fed MOD group (FO/MOD). The MOD groups received letrozole daily for 21 consecutive days at a concentration of 1 mg/kg by gavage, whereas the CON groups were fed daily with 1% CMC (1 ml/kg) for 21 consecutive days. Vaginal smears were collected daily at 9:00 am and measured with Wright–Giemsa staining for all of the rats. The stage of cyclicity was determined by a microscopic analysis of the predominant cell type. The four phases of the estrus cycle are comprised of different predominant cells: proestrus, predominately consisting of nucleated epithelial cells; estrus, predominately consisting of cornified epithelial cells; metestrus, equal mix of leukocytes, nucleated epithelial cells, and cornified epithelial cells; and diestrus, predominately consisting of leukocytes. The observation period lasted for 77 consecutive days beginning on the first dose of letrozole until the last day of treatment.

Ovary Hematoxylin and Eosin Staining
After sacrificing the rats, the ovarian tissue samples were immediately fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned at 4 μm. To evaluate ovary damage, every 10th section (n = 8) was mounted on a glass slide, stained with hematoxylin and eosin (H&E), and analyzed using an Olympus light microscope (Melville, NY, USA) by two persons blinded to the origin of the sections. The numbers of cystic follicles and corpora lutea were counted. According to ovarian H&E continuous diestrus phase predominantly exhibiting leukocytes, suggesting that the PCOS model was successful. After modeling, the FO groups received 1 ml/kg of FO daily for 8 weeks by gavage; the PF groups were administrated with 1% CMC (1 ml/kg) daily. The establishment of the PCOS rat model was comparable to that of a previous description (41). Body weight (BW) was measured weekly during 3 weeks of modeling and the subsequent 8 weeks of therapy. The estrous cycle was estimated by collecting vaginal smears daily. At the end of the experiment, all rats were euthanized and associated indications were investigated. Fecal samples and vaginal secretions were snap-frozen and stored at −80°C. The plasma samples were isolated by centrifugation and stored at −80°C.

Vaginal Smear
Vaginal smears were collected and measured with Wright–Giemsa staining for all of the rats daily at 9:00 am. The stage of cyclicity was determined by a microscopic analysis of the predominant cell type. After 21 days of intervention, the rats were under a
staining, the number of cystic follicles and corpus luteum as well as the area of three ovarian tissues was detected in diverse groups. Based on the average value of ovarian tissue area in the negative control group, the number of cystic follicles and corpus luteum in the other three groups was corrected. According to the criteria proposed previously, cystic follicles were defined as those follicles devoid of oocytes, displaying a large antrum cavity, an enlarged thecal cell layer, and a thin granulosa cell compartment containing apparently healthy cells (42).

**Determination of Plasma Sex Steroid Hormones**

In order to evaluate the level of sex steroid hormones in rats, plasma was obtained to determine the respective follicle-stimulating hormone (FSH), luteinizing hormone (LH), E2, T, progesterone (PROG), as well as sex hormone binding globulin (SHBG), using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturers’ instructions (Shanghai Jianglai Biotech, Shanghai, China). The sensitivities of the assays were 0.1 IU/L, 0.1 mIU/ml, 0.1 pmol/L, 1.0 pg/ml, 0.1 nmol/L, and 0.1 ng/ml for FSH, LH, E2, T, PROG, and SHBG, respectively. For each hormone, the intra- and inter-assay coefficients of variation were <9 and <11%. Each sample was tested in triplicate.

**Plasma Lipid Metabolism**

The biochemical indications of lipid metabolism, including plasma total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), were respectively determined using AU400 automatic biochemical analyzer (Olympus, Japan).

**Insulin Resistance Tests**

Insulin resistance was applied to the homeostasis model assessment of insulin resistance (HOMA-IR), which was calculated as [fasting plasma glucose (FPG) (mmol/L) × fasting insulin concentrations (FINS) (mIU/L)]/22.5. After fasting for 8 h, the FPG from one drop of tail blood was measured by using a standard glucometer (One Touch Profile, Johnson & Johnson, Inc. Milpitas, CA, USA). The plasma FINS was measured with a commercial ELISA kit (Fankewei Biology, Shanghai, China).

**Determination of Plasma and Ovarian Inflammatory Indicators**

Plasma and ovarian inflammatory cytokines including IL-1β, IL-6, IL-10, IL-17A, and TNF-α were measured by using ELISA kits according to the manufacturer's instructions (Shanghai Jianglai Biotech, Shanghai, China). The monocyte chemoattractant protein-1 (MCP-1) was measured by using ELISA kits (Fankewei Biology, Shanghai, China). The sensitivities of the assays were 0.1, 1.0, 0.1, 0.1, 1.0, and 0.1 pg/ml for IL-1β, IL-6, IL-10, IL-17A, TNF-α, and MCP-1, respectively. Each sample was tested in triplicate. The plasma LPS levels in each group were examined using a limulus amebocyte lysate kit (Xiamen Bioendo Technology Co., Ltd, Xiamen, China) according to the manufacturer's instruction. Briefly, 50 µl of diluted plasma (1:4 dilutions with endotoxin-free water) was dispensed to each well in a 96-well plate. At the initial time point, 50 µl of the limulus amebocyte lysate reagent was added, respectively. The plate was incubated at 37°C for 30 min. Then, 100 µl of the chromogenic substrate warmed to 37°C was added to each well, and incubation was extended for an additional 6 min at 37°C. The reaction was stopped by adding 100 µl of 25% solution of glacial acetic acid. Optical density at 545 nm was measured with a microplate reader (Thermo Scientific, USA).

**Gut Microbiota and VMB Sequencing Analysis**

After 8 weeks of treatment, five rats from each group were randomly selected and placed in sterilized cages. Fresh feces and vaginal secretions of diverse rats were, respectively, collected and immediately stored at −80°C for subsequent DNA extraction. The rats were put into a clean cage with aseptic filter paper, the end of the tail and rectum of which was squeezed gently. Then, feces were collected with sterile tweezers in a sterile Eppendorf tube after defecation and transferred to −80°C for preservation immediately. Moreover, the vaginal orifice of rat was disinfected with alcohol cotton balls. After drying, we took a new aseptic cotton swab and inserted it into the vagina and rotated it gently. Then, the cotton swab with vaginal secretions was taken out and separated by aseptic scissors as well as stored at −80°C immediately for subsequent DNA extraction. The protocols for sample processing, 16S ribosomal DNA gene amplification, sequencing, and statistical analysis of microbiota data were performed as described previously (43).

Extraction of bacterial DNA by cetyltrimethylammonium ammonium bromide (CTAB) was performed by adding the appropriate amount of lysozyme and sample to 1,000 µl CTAB lysate. The mixture was placed in a 65°C water bath and mixed by inversion several times in order to facilitate the complete lysis of the sample. Next, phenol (pH 8.0), chloroform, and isooamyl alcohol were added to the supernatant after centrifugation so that the ratio of the three was 25:24:1, with mixing by inversion and centrifugation at 12,000 × g for 10 min. In the same way, chloroform and isooamyl alcohol (24:1) were added to the obtained supernatant, followed by centrifugation. The collected supernatant was added with isopropanol. The mixture was precipitated at −20°C after shaking up and down. Then, the mixture was centrifuged again according to the previous centrifugation conditions. The obtained precipitate was washed twice with 1 ml 75% ethanol. Then, the precipitate was blown dry on a clean bench or air-dried at room temperature. The DNA samples were dissolved in ddH2O. If the sample was difficult to dissolve, it needed to be incubated at 55–60°C for 10 min. Finally, 1 µl of RNase A was added to the dissolved DNA sample, which was allowed to be kept at 37°C for 15 min to obtain bacterial DNA. The extracted DNA was stored at −20°C until application.

The DNA sequences involving the V3 and the V4 regions of the 16S rDNA hypervariable regions were amplified by Phusion® High-Fidelity PCR Master Mix with GC Buffer (New England Biolab, USA) using the following primers (5’ to 3’): 341F-CCTAYGGGRBGCASCAG, 806R-GGACTACNNGGGTATCTAA. The PCR product was...
analyzed and separated on 2% agarose gel, which was purified using the GeneJE Gel Recovery Kit (Thermo Scientific, USA). The library was constructed using the TruSeq® DNA PCR-Free Sample Preparation Kit in order to carry out Qubit quantitation and library detection. After passing the test, the library was sequenced using the illumina HiSeq 2500 platform by Beijing Novogene Technology Co., Ltd., China.

**Measurement of the Feces SCFA Concentrations**

Standard acetic acid, propionic acid, butyric acid, and valerate acid at a minimum purity of 98% were obtained from Sigma-Aldrich (St. Louis, MO, USA). Phosphoric acid and ether of analytical grade were purchased from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China). SCFA (acetic acid, propionic acid, butyric acid, and valeric acid) measurements were carried out on a single quadrupole mass spectrometer (5975B-MSD) equipped with 6890N GC (Agilent Technologies, Santa Clara, CA, USA). The samples were mixed with a QL-866 vortex meter (Haimen, Jiangsu, China) and separated from H1850R refrigerated centrifuge (Xiang Yi, Changsha, Hunan, China). A mixed standard stock solution of the four SCFAs was prepared by dissolving an accurately weighed quantity of ether. Working solution series were prepared by appropriate dilutions of mixed standard stock solutions. A 1-point calibration curve was made by adding the working solutions and an equal volume of IS solution covering a range from 0.05 to 250 μg/ml (0.05, 0.1, 0.5, 1, 5, 10, 25, 50, 100, and 250 μg/ml). All these solutions were stored in a freezer at 0°C prior to use. Fecal samples weighing 100 mg were homogenized in 100 μl of 15% phosphoric acid with 100 μl of 250 μg/ml isohexanoic acid solution as IS and 400 μl ether (70 Hz for 1 min). Subsequently, the samples were centrifuged at 4°C for 10 min (12,000 x g), and the supernatants were transferred into a vial prior to the GC-MS analysis. The GC was fitted with a capillary column Agilent HP-INNOWAX (30 m x 0.25 mm i.d. x 0.25 μm) (Agilent Technologies, Santa Clara, CA, USA), and helium was used as the carrier gas at 1 ml/min. Injection was made in split mode at 10:1, with an injection volume of 1 μl and an injector temperature of 250°C. The temperature of the ion source, interface, and quadrupole were 230, 250, and 250°C, respectively. The column temperature was initially 90°C and then increased to 120°C at 10°C/min, to 150°C at 5°C/min, and finally to 250°C at 5°C/min; and this temperature was kept for 2 min (total run-time of 15 min). The detector was operated in electron impact ionization mode (electron energy 70 eV) using full scan and single ion monitoring (SIM) mode.

**Statistical Analysis**

Statistical analysis was performed using GraphPad Prism software 6.01 (GraphPad Software Inc., CA, USA) and SPSS 17.0 (IBM Corp., NY, USA). All experimental data were expressed as mean ± standard deviation of at least three independent experiments. Data were determined by one-way analysis of variance to compare the mean values of variables among the groups. Bonferroni’s test or Tukey’s post hoc test was used to identify the significance of pairwise comparison of mean values among the groups. Moreover, Spearman’s correlation analysis was performed to identify the correlations between microbiota and inflammatory indicators. P < 0.05 was considered to be statistically significant.

**RESULT**

**Dietary FO Supplementation Improved the Estrous Cycles of Letrozole-Induced PCOS in Rats**

Wright–Giemsa staining was used to estimate the difference of estrous cycles in diverse groups. Rats in the PF/CON and FO/CON groups exhibited regular estrous cycles of 4–5 days, comprising of proestrus, estrus, metestrus, and diestrus (Figures 2A–F). However, after 18 days of intervention, rats in the PF/MOD group were under a continuous diestrus phase, predominantly exhibiting leukocytes (Figure 2G). Intriguingly, after 20 days of dietary FO intervention, a cyclical variation from nucleated epithelial cells to cornified epithelial cells to a mix of leukocytes, nucleated epithelial cells, and cornified epithelial cells was microscopically observed (Figure 2H), suggesting that dietary FO can improve the disorder of estrous cycle in letrozole-induced PCOS.

**Dietary FO Ameliorated Ovarian Injury in PCOS**

Ovary weights in the PF/MOD group were increased with a fairly smooth-white appearance, compared with those in PF/CON group (P = 0.0103, Figures 3A,B). However, dietary FO improved the ovarian morphology and the ovary weights (P = 0.0153, Figure 3B). Moreover, H&E staining was used to determine the alteration of ovarian pathology in diverse groups (Figures 3C–J). Ovaries in the PF/CON and FO/CON groups possessed follicles and fresh corpora lutea (Figures 3C,D,G,H). The granulosa within follicles in the control group showed multiple layers. Compared to the PF/CON group, the number of cystic follicles in the PF/MOD group was increased (P = 0.0027, Figure 3L), but the corpus luteum decreased or disappeared (P = 0.0016, Figure 3K), indicating that the ovulatory function of the letrozole-induced PCOS model was impaired. Importantly, dietary FO administration increased the formation of corpora lutea (P = 0.0025, Figure 3L) as well as decreased the number of cystic follicles (P = 0.024, Figure 3K), demonstrating that dietary FO ameliorated the pathological damage of ovarian tissue and ovulatory function.

**Plasma Levels of Sex Steroid Hormones**

To assess the effects of FO on sex steroid hormones in PCOS, we measured six plasma sex hormones involving FSH, LH, E2, T, PROG, and SHBG using ELISA kit. The levels of LH showed no significant change in the diverse groups (P > 0.05, data not shown). However, the levels of LH/FSH and T in the PF/MOD group were significantly higher than those in the PF/CON group (P = 0.0038, P = 0.0054, Figures 4B,D) or the FO/MOD group (P = 0.017, P = 0.0063, Figures 4B,D). FSH, E2, and PROG were markedly reduced in the PF/MOD group compared to those of the PF/CON group (P = 0.0023, P = 0.009, P = 0.0024, Figures 4A,C,E) or the FO/MOD group (P = 0.0322, P = 0.004, P...
Dietary FO Reduced BWs and Dyslipidemia

The body weight growth curve of rats in diverse groups were shown in Figure 4G. There was no significant difference in the initial BWs among the four groups. After 11 weeks of intervention, the BWs in the PF/MOD group were dramatically increased compared to those in the PF/CON group ($P = 0.0013$, Figures 4A,C,E). Interestingly, after FO treatment, the final BWs in the FO/MOD group was significantly decreased compared to those in the PF/MOD group ($P = 0.027$, Figure 4H), demonstrating that dietary FO partially reduced the BWs in the PCOS model. To assess the effects of FO on lipid metabolism in PCOS, the plasma levels of TC, TG, HDL-C, and LDL-C were investigated, respectively. As shown in Figures 4I–K, TC, TG, and LDL-C were higher, while HDL-C was lower in the PF/MOD group than those in the PF/CON group ($P = 0.004$, $P = 0.0052$, $P = 0.0022$, $P = 0.0028$, Figures 4I–L) or the FO/MOD group ($P = 0.0153$, $P = 0.0274$, $P = 0.007$, $P = 0.002$, Figures 4I–L). These four lipid indicators showed no significant difference between the PF/CON group and the FO/CON group.

Dietary FO Reduced Plasma Insulin Resistance in PCOS

To further understand the characteristic insulin resistance in PCOS after dietary FO treatment, we assessed the levels of FPG, FINS, and HOMA-IR in diverse groups. FPG in the PF/MOD group was increased in comparison with that in the PF/CON group ($P = 0.014$, Figure 4M). The FO treatment reduced the FPG levels but without a significant difference (Figure 4M). Intriguingly, FINS and HOMA-IR in the PF/MOD group were significantly higher than those in the PF/CON group ($P = 0.016$, $P = 0.0018$, Figures 4N,O) or the FO/MOD group ($P = 0.0383$, $P = 0.0055$, Figures 4N,O).

Dietary FO Decreased Plasma and Ovarian Inflammation in PCOS

After dietary FO administration, we found elevated plasma levels of IL-1β ($P = 0.002$), IL-6 ($P = 0.0197$), IL-17A ($P = 0.0013$, Figures 4A,C,E). In addition, the levels of SHBG in the PF/MOD group were lower than those of the PF/CON group ($P = 0.009$, Figure 4F). The above results demonstrated that dietary FO treatment improved the sex steroid hormones in PCOS.
0.0218), TNF-α (P = 0.0015), and MCP-1 (P = 0.0165) in the PF/MOD group in comparison with those of the PF/CON group (Figures 5A,B,D–F). Moreover, dietary FO reduced the plasma levels of IL-1β (P = 0.0061), IL-6 (P = 0.0231), IL-17A (P = 0.031), TNF-α (P = 0.0013), and MCP-1 (P = 0.0325), respectively, compared to those of the FO/MOD group.
FIGURE 4 | Effects of flaxseed oil on body weights (BWs), lipid metabolism indicators, and sex steroid hormones in diverse groups. (A) Body weights growth curve. (B) Final BWs. (C) Plasma total cholesterol levels. (D) Plasma triglycerides levels. (E) Plasma high-density lipoprotein levels. (F) Plasma low-density lipoprotein levels. (G) Plasma follicle-stimulating hormone levels. (H) Plasma luteinizing hormone levels. (I) Plasma estradiol levels. (J) Plasma testosterone levels. (K) Plasma progesterone levels. (L) Plasma sex hormone-binding globulin levels. Effects of flaxseed oil on insulin resistance of diverse groups. (M) Plasma fasting plasma glucose levels. (N) Plasma fasting insulin levels. (O) Insulin resistance index. Data were expressed as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

(Figures 5A,B,D–F). However, plasma IL-10 in PF/MOD was lower than that in the PF/CON group (P = 0.0025, Figure 5C) or the FO/MOD group (P = 0.0315, Figure 5C). Similar results were observed in the ovarian tissues in the diverse groups (PF/CON vs. PF/MOD: IL-1β, P = 0.0121; IL-6, P = 0.0112; IL-10, P = 0.0165; IL-17A, P = 0.0055; TNF-α, P = 0.0074; MCP-1,
Effects of flaxseed oil on plasma and ovary inflammatory indicators of diverse groups. (A) Plasma and ovary interleukin 1\(\beta\) levels. (B) Plasma and ovary IL-6 levels. (C) Plasma and ovary IL-10 levels. (D) Plasma and ovary tumor necrosis factor \(\alpha\) levels. (E) Plasma and ovary IL-17A levels. (F) Plasma and ovary monocyte chemotactic protein 1 levels. (G) Plasma lipopolysaccharide levels. Data were expressed as mean ± SD. *\(P < 0.05\), **\(P < 0.01\).

Collectively, dietary FO reduced plasma and ovarian inflammation in PCOS by suppressing pro-inflammatory cytokines and enhancing anti-inflammatory IL-10.

\[ P = 0.012. \text{PF/MOD vs FO/MOD: IL-1\(\beta\), } P = 0.0135; \text{IL-6, } P = 0.0381; \text{IL-10, } P = 0.0295; \text{IL-17A, } P = 0.0104; \text{TNF-}\alpha, \text{ } P = 0.0072; \text{MCP-1, } P = 0.0088, \text{ Figures 5A–F).} \]

To further assess the effects of FO on gut dysbiosis, permeability, and integrality of gut barrier, plasma-translocated LPS derived from Gram-negative bacteria was detected by the limulus reagent. The plasma LPS concentration in the PF/MOD group was significantly higher than that in the PF/CON group (\(P = 0.0089, \text{ Figure 5G).}\) However, the LPS level in the FO/MOD
group was decreased compared to that in the PF/MOD group ($P = 0.0286$, Figure 5G), suggesting that supplementary FO may inhibit endotoximia in PCOS.

**Dietary FO Restored Gut Dysbiosis in PCOS**

Emerging evidences have demonstrated that the gut microbiota is an essential element in the occurrence and the development of PCOS (23, 44). In order to investigate the effect of dietary FO on the composition and the abundance levels of intestinal microbiota in PCOS, fecal samples were detected by 16S rRNA sequencing. Initially, as a result of $\alpha$-diversity analysis, the abundance and the diversity of the bacterial community were assessed by observed species index and rarefaction curve. It was observed that the rarefaction curve tended to be flat when the sequence number increased to 20,000, indicating that the amount of sequencing data was reasonable (Figure S1B). The results, including both observed species index and rarefaction curve, showed no difference by Tukey test or Wilcoxon rank sum test ($P > 0.05$, Figures S1A,B).

Next, we assessed the $\beta$ diversity of gut microbiota in diverse groups using unweighted principal coordinate analysis (PCoA) and weighted distance matrices (nonmetric multidimensional scaling, NMDS) (Figure 6 and Figure S2). The PCoA analysis showed that the general composition of the gut microbiota in the PF/MOD group was obviously different from that

![PCoA plot](image1.png)  
**A** PCoA plot  
**B** PCoA plot  
**C** PCoA plot  
**D** PCoA plot

**FIGURE 6** | Principal coordinate analysis showing differences in fecal samples in terms of species. Beta diversity was on unweighted Unifrac. (A) PF/CON vs. PF/MOD. (B) PF/CON vs. FO/CON. (C) PF/MOD vs. FO/MOD. (D) FO/CON vs. FO/MOD.
in the PF/CON or FO/MOD groups, respectively (Figure 6). Similar results were obtained from the NMDS analysis (Figure S2).

Finally, we investigated the difference in gut microorganism at the phylum and the genus levels in diverse groups. At the phylum level, ∼90% of the gut bacteria in the diverse groups...
belong to *Firmicutes* and *Bacteroidetes*, another 8% comprised *Proteobacteria* and *Actinobacteria*, and the rest accounted for a low abundance (Figure 7A). The predominant *Firmicutes* and *Bacteroidetes* showed no significant change among the diverse groups. The ratio of *Firmicutes* to *Bacteroidetes* (F/B) in the PF/MOD group was higher than that in the PF/CON group (P = 0.0389, Figure 7C), but dietary FO decreased the F/B ratio in PCOS (P = 0.0453, Figure 6C). Similarly, the proportion of *Actinobacteria* in the PF/MOD group was obviously increased in comparison with that in the PF/CON group (P = 0.0363, Figure 7D). Dietary FO reduced the abnormal abundance of *Actinobacteria* in PCOS (P = 0.0182, Figure 7D). Collectively, the above results demonstrated that dietary FO supplementation had major effects on the ratio of F/B and *Actinobacteria*.

At the genus level, the relative abundance of *Lactobacillus* and *Allobaculum* in the FO/MOD group was higher than that in the PF/MOD group (P = 0.003, P = 0.0027, Figures 7E, G), whereas *Lactobacillus* and *Allobaculum* in the PF/CON group and the PF/MOD group showed no difference (P > 0.05, Figures 7E, G). The relative abundance of *Bacteroides* in the PF/MOD group was elevated compared to that in the PF/CON group (P = 0.0192, Figure 7F). Moreover, the proportions of *Butyrivibrio*, *Desulfovibrio*, *Ruminiclostridium*, and *Bifidobacterium* in the PF/MOD group were obviously decreased in comparison with those in the PF/CON group (P = 0.0186, P = 0.0063, P = 0.0051, P = 0.038, Figures 7H–K). Intriguingly, dietary FO
administration increased the relative abundance of *Butyrivibrio*, *Desulfovibrio*, and *Bifidobacterium*, compared with that in the FO/MOD group ($P = 0.0195$, $P = 0.0026$, $P = 0.032$, Figures 7H,I,K). However, dietary FO reduced the relative abundance of *Ruminoclostridium* in comparison with that in the PF/CON group ($P = 0.0182$, Figure 7J). Overall, dietary FO dramatically changed the abnormal proportions of genus components in PCOS by increasing *Lactobacillus*, *Allobaculum*, *Butyrivibrio*, *Desulfovibrio*, and *Bifidobacterium* as well as decreasing *Bacteroides*.

**Dietary FO Ameliorated VMB in PCOS**

Growing evidences have demonstrated that VMB are intimately linked to female fertility (19, 45). In order to investigate the role of VMB dysbiosis in PCOS, vaginal secretions in the four groups were detected by 16S rRNA sequencing. Observed species index showed that the abundance and the diversity of VMB in the PF/MOD group were lower than those in the PF/CON group ($P = 0.0123$, Figure S3A) and the FO/MOD group ($P = 0.0094$, Figure S3A). Moreover, rarefaction curve indicated that the amount of sequencing data was reasonable (Figure S3B). PCoA showed that VMB in the PF/MOD group was obviously different from that in the PF/CON group in terms of species in the vaginal secretions samples (Figure 8A). There was no obvious change in PCoA between the PF/CON group and the FO/CON group as well as the FO/MOD group (Figures 8B,D). Interestingly, supplementary FO seemingly altered the vaginal species compared to PF/MOD (Figure 8C). Similar results from the NMDS analysis were obtained (Figure S4).

Next, we investigated the difference of VMB in the phylum and the genus levels in the diverse groups. At the phylum level, we found that *Proteobacteria*, *Bacteroidetes*, and *Firmicutes* were predominant in the diverse groups (Figure 9A). There was no notable difference in the relative abundances of *Proteobacteria* between the PF/CON group and the FO/MOD group (Figure 9C), whereas dietary FO decreased the proportion of *Proteobacteria* in the disease ($P = 0.017$, Figure 9C). Besides that, the level of *Firmicutes* in the PF/MOD group was lower than that in the PF/CON group ($P = 0.0048$, Figure 9D). Collectively, the above data indicated that dietary FO possessed major effects on *Proteobacteria*.

At the genus level (Figure 9B), the relative abundances of *Lactobacillus*, *Faecalibacterium*, and *Parabacteroides* were increased, while *Streptococcus* was decreased in the FO/MOD group compared to the PF/MOD group ($P = 0.0101$, $P = 0.0198$, $P = 0.0188$, $P = 0.0196$, Figures 9E–H). Moreover, *Lactobacillus* in the PF/MOD group was significantly decreased compared to that in the control group ($P = 0.0234$, Figure 9F). Additionally, *Streptococcus* abundance in the FO/MOD group was higher than that in the PF/CON group ($P = 0.0339$, Figure 9G). However, both *Faecalibacterium* and *Parabacteroides* in the PF/CON group and the PF/MOD group showed no difference ($P > 0.05$, Figures 9E,H). Taken together, dietary FO visibly changed the initial proportion of VMB in PCOS by increasing *Lactobacillus*, *Faecalibacterium*, and *Parabacteroides* as well as decreasing *Streptococcus*.

**Dietary FO Modulated the SCFAs of Gut Microbiota in PCOS**

SCFAs belong to the crucial metabolites of the gut microbiota, mainly including acetic acid, propionic acid, butyric acid, and pentanoic acid. The TIC chromatogram showed that every SCFA can be distinguished clearly and exhibited a good peak shape, indicating that the method and data were reliable (Figure 10A). As a result of detection by liquid chromatography-mass spectrometry, acetic acid ($P = 0.0009$), propionic acid ($P = 0.0011$), butyric acid ($P = 0.003$) as well as pentanoic acid ($P = 0.0160$) in the PF/MOD group were significantly decreased compared with those in the PF/CON group (Figures 10B–E). Intriguingly, the decreased levels of SCFAs in PCOS were restored by dietary FO administration (acetic acid: $P = 0.0145$, propionic acid: $P = 0.0027$, butyric acid: $P = 0.001$, and pentanoic acid: $P = 0.0124$, Figures 10B–E).

**Correlation Analysis**

For the assessment of relationships among hormones, gut microbiota/VMB, and inflammation in PCOS, we performed a correlation analysis (Figure 11). The abundance of anti-inflammatory bacteria including *Lactobacillus*, *Firmicutes*, *Butyrivibrio*, *Desulfovibrio*, and *Bifidobacterium* were positively correlated with SCFAs, FSH, E2, PROG, and IL-10, respectively. However, they were negatively associated with LPS, FSH/LH, T, and pro-inflammatory indicators. Reversely, the abundance of “bad bacteria” including *Actinobacteria*, *Bacteroidetes*, and *Streptococcus* as well as the F/B ratio showed a negative correlation with SCFAs, FSH, E2, PROG, and IL-10, respectively. Moreover, the abovementioned pro-inflammatory bacteria were positively correlated with LPS, FSH/LH, T, and pro-inflammatory indicators, respectively. Additionally, the rest of the different bacteria, including *Allobaculum*, *Ruminiclostridium*, *Proteobacteria*, *Faecalibacterium*, and *Parabacteroides*, were only connected with a few parameters, such as PROG. Taken together, there were close interactions and correlations among gut/vaginal bacteria, inflammation, and sex steroid hormones.

**DISCUSSION**

In the present study, the therapeutic effects and the associated mechanisms of dietary FO supplementation on letrozole-induced PCOS rats were investigated through determining the sex steroid hormones, lipid metabolism, insulin resistance, inflammation, and gut/vaginal microbiota. Here we demonstrated that the potent effects of dietary FO on PCOS may integrally be due to modulating the hormones–inflammation–gut/vaginal microbiota axis, potentially providing an inexpensive intervention for the control of PCOS.

Firstly, the letrozole-induced PCOS model used in this study has been widely utilized to assess the effects and the mechanisms of interventions on precautions and pathogenesis in PCOS (46–48). Letrozole, an aromatase inhibitor, induces hyperandrogenemia by reducing the conversion of T to estrogen (49). Accumulated human and animal studies have demonstrated that omega-3 PUFAs docosahexenoic acid (DHA)
and eicosapentaenoic acid (EPA) may ameliorate PCOS progression (50, 51). Anovulation was dramatically improved by DHA supplementation (52). In this study, the improvement of the disrupted estrous cycle and ovulatory function after dietary FO treatment demonstrated that ALA-rich FO possessed the ability to ameliorate PCOS, indicating that inexpensive FO exhibited similar effects with EPA and DHA. We speculate that in vivo interconversion among FO, EPA, and DHA may partially contribute to understanding this effect of omega-3 PUFAs. However, the dynamic interconversion after FO supplementation needs to be further determined.

PCOS represents a chronic endocrine–metabolic disease with hyperandrogen and low estrogen (53). The LH/FSH ratio was regarded as a main biomarker of diagnosis in PCOS (54, 55). The notably increased T level is usually considered as a marker of hyperandrogenism in PCOS (56). During the development and the progression of PCOS, abnormally increased T secretion suppresses the production of E2, SHBG, and FSH (57–59). Furthermore, the suppressed FSH results in the arrest of ovarian folliculogenesis and corpora lutea under the synergistic effect of LH, thereby decreasing the PROG produced by the corpus luteum (60). SHBG produced by the liver, a transporter of sex hormones with a high affinity for T but a low affinity for E2, can be used to evaluate the severity of hyperandrogenism and the therapeutic efficacy (61). In this study, abnormal elevated plasma T and LH/FSH ratio, as well as reduced levels of

![Graphs showing microbial species abundance](https://example.com/graphs)
plasma FSH, E2, SHBG, and PROG in PCOS, was notably rectified by FO intervention, demonstrating that dietary FO supplementation was capable of improving the homeostasis of sex steroid hormones in PCOS. A study indicates that an intake of dietary EPA exerted beneficial effects on androgens in PCOS (62). Moreover, EPA treatment increases the number of follicular cell layers and decreased the levels of LH and T in PCOS (27).

Recent studies have shown that patients with PCOS were mainly accompanied with dyslipidemia and insulin resistance, which might be caused by hyperandrogenism (63, 64). Omega-3 fatty acids may be recommended for the treatment of PCOS patients with insulin resistance as well as high TC and TG (51). Consistent with previous findings (65, 66), decreases of TC, TG, and LDL levels, but an increase of HDL, after dietary FO
treatment demonstrated that dietary FO improved dyslipidemia in PCOS. Additionally, we found that dietary FO intervention reduced the levels of FINS and HOMA-IR, which was consistent with the findings of previous studies (67, 68). Supplementation of fish oil rich in omega-3 fatty acids can elevate the adiponectin levels to stimulate AMPK in the muscle to downstream oxidative pathways and to finally improve insulin sensitivity (67, 68). However, the role of the AMPK pathway in the amelioration of insulin resistance after dietary FO supplementation needed to be further investigated.

Numerous studies have demonstrated that a chronic low-grade degree of inflammation plays a critical role in the development of PCOS (69, 70). In our study, we indicated that dietary ALA-rich FO alleviated systemic and ovarian inflammation via suppressing the pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-17A, and MCP-1) and elevating the anti-inflammatory IL-10, suggesting the anti-inflammatory role of inexpensive dietary FO administration in PCOS. A previous report illustrated that omega-3 PUFAs and vitamin E co-supplementation down-regulated IL-8 and TNF-α expression in PCOS patients (71). Dietary ALA-rich FO inhibited the production of TNF-α, IL-1β, and IL-6 in T2DM and ALD (37, 38). EPA treatment can decrease IL-1β and TNF-α but increase IL-10 in PCOS (27). Clinical studies have shown that the supplementation of omega-3 PUFAs is beneficial in decreasing the MCP-1 expression in macrophages and the levels of endothelial chemokine (72, 73). Due to accumulating evidences on the critical role of macrophages in the pathogenesis of PCOS, we speculate that the anti-inflammatory effect of dietary FO may attribute to the inhibition of the activation of macrophages and its polarization. The exact role of the macrophage in the underlying mechanism of FO-treated PCOS needs to be further investigated.

Growing evidences have demonstrated that the gut microbiota and their metabolites are closely associated with the occurrence and the development of PCOS (18, 74–76). Liu et al. found a
decrease in Ruminococcaceae and an increase in gram-negative bacteria, including Bacteroides and Desulfovibrio, in women with PCOS, which was consistent with our research (20). Regarding to the phylum level of the gut microbiota, we found that the abundances of Firmicutes, Bacteroidetes, and Proteobacteria were the most dominant in all groups, in consistency with previous studies (12, 77). An increase in Firmicutes/Bacteroidetes ratio is closely related to obesity (12, 78). We found that the increased ratio of F/B in PCOS was rectified by dietary FO administration. Moreover, in the genus level, our results showed that FO restored gut dysbiosis in PCOS by up-regulating Lactobacillus, Allobaculum, Desulfovibrio, and Bifidobacterium and down-regulating Actinobacteria and Bacteroides, suggesting that dietary FO attenuated PCOS via restoring the gut dysbiosis. Similarly, dietary prebiotic inulin supplementation ameliorated PCOS in mice via improving the gut microbiota (23). A recent clinical study found that Bifidobacterium lactis V9 was significantly decreased in patients with PCOS. This probiotic regulated the secretion of sex hormones in PCOS patients through the gut–brain axis (22).

Microbial LPS and SCFAs are thought to play a pivotal role in regulating inflammation and metabolism in PCOS (79, 80). LPS, derived from gram-negative bacteria, activates the inflammation of the peripheral circulation and the ovary through the TLR4-NF-κB signaling pathway in macrophage to release inflammatory cytokines (74). In this study, abnormal plasma LPS was restored by dietary FO treatment, demonstrating that FO improved gut dysbiosis and the gut barrier to decrease the intestinal permeability of LPS translocation from the intestines to the systematic circulation in PCOS, finally contributing to the suppression of systematic and ovarian inflammation. In addition, the microbial fermentation end-products SCFAs are pivotal in the regulation of intestinal permeability and inflammation in the gut and the systemic circulation (81). The anti-inflammatory and the immunomodulatory effects of SCFAs might be due to the activation of specific cell receptors G-protein-coupled receptor (GPR) 109a, GPR41, and GPR43 and the intracellular target via inhibiting histone deacetylase activity (82–85). In this study, elevated SCFA levels, including acetic acid, propionic acid, butyric acid, and valeric acid, after dietary FO treatment may subsequently result in enhancing the integrity of the intestinal mucosal barrier as well as inhibiting enteral and parenteral inflammation. We consider that the alteration of SCFAs may probably regulate inflammation through the SCFAs–GPR–inflammatory cells signaling pathway, which is ongoing to investigated in our subsequent research. Additionally, other microbial metabolites may be involved in the effects of dietary FO intervention on PCOS and need to be further investigated using metabolomics methodology.

Studies have indicated that VMB plays a crucial role in the development of reproductive and HPV/HIV infectious diseases (86–89). However, the effects of the proportions of VMB on PCOS are rarely reported. In this study, we firstly demonstrated a reduction of the abundance and the diversity of VMB in PCOS. The richness and the diversity of the VMB significantly affected host reproductive ability, metabolic function, as well as the defense ability of immune system (90). A reduction in VMB diversity led to a lack of estrogen-metabolizing bacteria and thereby decreasing the circulating estrogen, which may induce a hypoestrogen-related disease. Moreover, we found that dietary FO altered VMB via up-regulating Lactobacillus, Faecalibacterium, and Parabacteroides as well as down-regulating Proteobacteria and Streptococcus. Lactobacillus in VMB can generate acidic fermentation products (primarily lactic acid) which serve to create an acidic environment to restrict the growth of most pathogens in the vagina (91). The ability of Lactobacillus to inhibit infection without inducing inflammation may maximize fecundity and successful pregnancy outcome in women (92, 93). Additionally, Faecalibacterium is a commensal bacterium, the absence of which may be associated with lipid metabolism and inflammation in Crohn’s disease (94). Studies on the effects of VMB in reproductive and gynecological diseases are still limited and largely unknown, which needs to be further studied.

In this study, we found that sex steroid hormones, gut/vaginal microbiota, and inflammation were closely correlated. The abundances of beneficial bacteria (Lactobacillus, Firmicutes, Butyrvirbio, Desulfovibrio, and Bifidobacterium) were positively correlated with SCFAs and E2, while these are negatively associated with LPS, T, and pro-inflammatory indicators. Reversely, Actinobacteria, Bacteroides, and Streptococcus were negatively correlated with SCFAs and E2, whereas these were positively correlated with LPS, T, and pro-inflammatory indicators. Recent studies indicated the bi-directional regulation of the gut microbiota and circulating estrogen levels (95). E2 level may improve bacterial virulence by inhibiting quorum sensing signaling. PROG has been proven to promote the growth of Bacteroides and Prevotella (96, 97). The gut microbiome promotes the enterohepatic circulation of estrogenic metabolites in the host through the secretion of β-glucuronidase enzymes to hydrolyze estrogenic glucuronides, increasing the reabsorption of estrogens into the blood and reducing elimination from the body (95, 98, 99). Additionally, the microbial fermentation end-products SCFAs (butyrate) can suppress the levels of pro-inflammation cytokines and LPS and enhance the gut mucosa integrity by up-regulating the expression of tight junction proteins and the production of retinoic acid (100–102).

**CONCLUSIONS**

This study highlighted that dietary FO ameliorated PCOS via the sex steroid hormones–gut/vaginal microbiota–inflammation axis in rats, which may potentially serve as an inexpensive intervention for the control of PCOS patients, especially those who are vegetarians.

**DATA AVAILABILITY STATEMENT**

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: NCBI, accession number PRJNA624034.
ETHICS STATEMENT

The animal study was reviewed and approved by the Ethics Committee of Ningxia Medical University (No. 2016-017).

AUTHOR CONTRIBUTIONS

HW, TW, and XZ designed and wrote the paper. TW, LS, YL, LZ, ZW, KL, HL, TB, LG, HW, and XZ performed the research. All authors have read and approved the final manuscript.

FUNDING

This work was supported by the first class discipline project in the College of Traditional Chinese Medicine in Ningxia Medical University, China (NXYLXK2017A06), the research project of Ningxia Medical University, China (Grant No. XT2018007), the research and development plan of the 13th Five-Year Plan of Ningxia Autonomous Region (the major S&T projects), China (Grant No. 2016BZ02), the first class discipline construction project in the colleges and universities of Ningxia, China (Grant No. NXYLXK2017A05), and the Ningxia high school first-class disciplines (West China first-class disciplines, Basic Medical Sciences of Ningxia Medical University), China (Grant No. NXYLXK2017B07).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2020.00284/full#supplementary-material

Figure S1 | Alpha-diversity analysis showing differences in diverse groups in terms of abundance and diversity of gut microbiota. (A) Observed species index. (B) Rarefaction curve.

Figure S2 | Nonmetric multidimensional scaling analysis showing differences in fecal samples in terms of species. Beta diversity was on weighted distance matrices. (A) PF/CON vs. PF/MOD. (B) PF/CON vs. FO/CON. (C) PF/MOD vs. FO/MOD. (D) FO/CON vs. FO/MOD.

Figure S3 | Alpha-diversity analysis showing differences in diverse groups in terms of abundance and diversity of vaginal microbiota. (A) Observed species index. (B) Rarefaction curve.

Figure S4 | Nonmetric multidimensional scaling analysis showing differences in vaginal secretion samples in terms of species. Beta diversity was on weighted distance matrices. (A) PF/CON vs. PF/MOD. (B) PF/CON vs. FO/CON. (C) PF/MOD vs. FO/MOD. (D) FO/CON vs. FO/MOD.

Table S1 | Determination of fatty acids in organic flaxseed oil.

REFERENCES

1. Nestler JE. Polycystic ovary syndrome. N Engl J Med. (2016) 375:1398. doi: 10.1056/NEJMc1610000

2. Baptiste CG, Battista MC, Trotti A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. (2010) 122:42–52. doi: 10.1016/j.jsbmb.2009.12.010

3. Homburg R. Polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. (2008) 22:261–74. doi: 10.1016/j.bpobgyn.2007.07.009

4. Siristatidis C, Sergentanis TN, Vogiatzi P, Kanavidis P, Chrelias C, Andreeva EN, Melnichenko GA, Grigoryan OR, Zhemaite NS, Volevodz NN. Androgens inhibit aromatase expression through DAX-1: insights into the molecular link between hormone balance and Leydig cancer development. Endocrinology. (2015) 156:1251–62. doi: 10.1210/en.2014-1654

5. Krishnan A, Muthusami S. Hormonal alterations in PCOS and its influence on bone metabolism. J Endocrinol. (2017) 232:R99–113. doi: 10.1530/JOE-16-0405

6. Dumesic DA, Lobo RA. Cancer risk and PCOS. Best Pract Res Clin Obstet Gynaecol. (2012) 27:338–41. doi: 10.1016/j.sjpobgyn.2011.12.008

7. Grigoryan OR, Zhemaite NS, Volevodz NN, Andreeva EN, Melnichenko GA, Dedov II. Long-term consequences of polycystic ovary syndrome. Ter Arkh. (2017) 89:75–9. doi: 10.17116/terarkh2017891075-79

8. Balen A. The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology. Best Pract Res Clin Obstet Gynaecol. (2004) 18:685–706. doi: 10.1016/j.bpbgyne.2004.05.004

9. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. (2005) 352:1223–36. doi: 10.1056/NEJMc1610000

10. Goodarzi MO, Lobo RA. Cancer risk and PCOS. Steroids. (2013) 78:782–9. doi: 10.1016/j.steroids.2013.04.004

11. Grigoryan OR, Zhemaite NS, Volevodz NN, Andreeva EN, Melnichenko GA, Dedov II. Long-term consequences of polycystic ovary syndrome. Ter Arkh. (2017) 89:75–9. doi: 10.17116/terarkh2017891075-79

12. Balen A. The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology. Best Pract Res Clin Obstet Gynaecol. (2004) 18:685–706. doi: 10.1016/j.bpbgyne.2004.05.004

13. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. (2005) 352:1223–36. doi: 10.1056/NEJMc1610000

14. Lanzino M, Maris P, Sirianni R, Barone I, Casaburi I, Chimento A, et al. DAX-1, as an androgen-target gene, inhibits aromatase expression: a novel mechanism blocking estrogen-dependent breast cancer cell proliferation. Cell Death Dis. (2013) 4:e274. doi: 10.1038/cddis.2013.235

15. Maris P, Campana A, Barone I, Giordano C, Morelli C, Malivindi R, et al. Androgens inhibit aromatase expression through DAX-1: insights into the molecular link between hormone balance and Leydig cancer development. Endocrinology. (2015) 156:1251–62. doi: 10.1210/en.2014-1654

16. Krishnan A, Muthusami S. Hormonal alterations in PCOS and its influence on bone metabolism. J Endocrinol. (2017) 232:R99–113. doi: 10.1530/JOE-16-0405

17. Kupreeva M, Diane A, Lehner R, Watts R, Ghosh M, Proctor S, et al. Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model. Am J Physiol Endocrinol Metab. (2019) 316:E1–33. doi: 10.1152/ajpendo.00018.2018

18. Insensier M, Murrri M, Del CR, Martinez-Garcia MA, Fernandez-Duran E, Escobar-Morreale HF. Gut microbiota and the polycystic ovary syndrome: influence of sex, sex hormones, and obesity. J Clin Endocrinol Metab. (2018) 103:2552–62. doi: 10.1210/jc.2017-02799

19. Ravel J, Gajer P, Abdö Z, Schneider GM, Koenig SS, McCulle SL, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA. (2011) 108 Suppl 1:4680–7. doi: 10.1073/pnas.1002611107

20. Liu R, Zhang C, Shi Y, Zhang F, Li L, Wang X, et al. Dysbiosis of gut microbiota associated with clinical parameters in polycystic ovary syndrome. Front Microbiol. (2017) 8:324. doi: 10.3389/fmicb.2017.00324

21. Qi X, Yun C, Sun L, Xia J, Wu Q, Wang Y, et al. Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome patients through the gut-brain axis. mSystems. (2019) 4:e00017–20. doi: 10.1093/mSystems.00017-2019

22. Zhang J, Sun Z, Jiang S, Bai X, Ma C, Peng Q, et al. Probiotic Bifidobacterium lactis V9 regulates the secretion of sex hormones in polycystic ovary syndrome patients through the gut-brain axis. mSystems. (2019) 4:e00017–19. doi: 10.1128/mSystems.00017-2019

23. Xue J, Li X, Liu F, Li K, Sha L, Yang X, et al. Inulin and metformin ameliorate polycystic ovary syndrome via anti-inflammation and modulating gut microbiota in mice. Endocr J. (2019) 66, 859–70. doi: 10.1507/endocrj.EJ18-0567
Wang et al. FO Ameliorates PCOS in Rats

24. Benschop CC, Quaak FC, Boon ME, Sijen T, Kuiper I. Vaginal microbial flora analysis by next generation sequencing and microarrays; can microbes indicate vaginal origin in a forensic context? Int J Leg Med. (2012) 126:303–10. doi: 10.1007/s00414-011-0660-8

25. Griffin C. Probiotics in obstetrics and gynecology. Aust N Z J Obstet Gynaecol. (2015) 55:201–9. doi: 10.1111/ajog.12303

26. Artimani T, Karimi J, Mehdezadeh M, Yaoangi M, Khanlarezadeh E, Ghorbani M, et al. Evaluation of pro-oxidant-antioxidant balance. (PAB) and its association with inflammatory cytokines in polycystic ovary syndrome. (PCOS). Gynecol Endocrinol. (2018) 34:148–52. doi: 10.1080/09535350.2017.1371691

27. Wang Y, He J, Yang J. Eicosapentaenoic acid improves polycystic ovary syndrome in rats via sterol regulatory element-binding protein 1. (SREBP-1)/toll-like receptor 4. (TLR4) pathway. Med Sci Monit. (2018) 24:2091–7. doi: 10.12659/MSM.909098

28. Rizzotto L, Fava F, Tuohy KM, Selmi C. Connecting the immune system, systemic chronic inflammation and the gut microbiome: the role of sex. J Autoimmun. (2018) 92:12–34. doi: 10.1016/j.jaut.2018.05.008

29. Org E, Mehrabian M, Parks BW, Shippova P, Liu X, Drake TA, et al. Sex differences and hormonal effects on gut microbiota composition in mice. Gut Microbes. (2016) 7:313–22. doi: 10.1089/gm.2016.7.313

30. Neuman H, Debelius JW, Knight R, Koren O. Microbial endocrinology: the role of the gut microbiota differs between women with a history of infertility and fertile women. Aust N Z J Obstet Gynaecol. (2018) 58:341–8. doi: 10.1111/ajog.12754

31. Atef MM, Abd-Elatif RN, Eman MN, Abo EGR, Aamer MA, Hafez YM. Therapeutic potential of sodium selenite in letrozole induced polycystic ovary syndrome rat model: Targeting mitochondrial approach. (selenium in PCOS). Arch Biochem Biophys. (2019) 671:245–54. doi: 10.1016/j.abb.2019.06.009

32. Khaled N, El-Bahy AA, Radwan R, Handoussa H, AbdelMaksoud S. Ocimum kilimandscharicum L. restores ovarian functions in letrozole-induced polycystic ovary syndrome. (PCOS) in rats: comparison with metformin. Life Sci. (2019) 232:116640. doi: 10.1016/j.lfs.2019.116640

33. Shao YY, Zhang ZP, Cheng Y, Wang XC, Zhang JP, Feng XJ, et al. Shaoyao-Gancao decoction alleviated hyperandrogenism in a letrozole-induced rat model of polycystic ovary syndrome by inhibition of NF-kappaB activation. Biosci Rep. (2019) 39:BSR20181877. doi: 10.1042/BSR20181877

34. Corbin CJ, Trant JM, Walters KW, Conley AJ. Changes in testosterone metabolism associated with the evolution of placental and gonadal isozymes of porcine aromatase cytochrome P450. Endocrinology. (1999) 140:520–2. doi: 10.1210/endo.140.1.7140

35. Hu X, Weng X, Tian Y, Wang C, Yang X, Yu K, et al. Effects of omega-3 polyunsaturated fatty acids on steroidogenesis and cellular development in PCOS rats. Food Funct. (2019) 10:2504–14. doi: 10.1039/C8FO02319K

36. Yang K, Zeng L, Bao T, Ge J. Effectiveness of omega-3 fatty acid for polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol. (2018) 16:227. doi: 10.1186/s12958-018-0346-x

37. Mostafa AF, Samir SM, Nagib RM. Omega-3 polyunsaturated fatty acid docosahexaenoic acid and its role in exhaustive-exercise-induced changes in female rat ovulatory cycle. Can J Physiol Pharmacol. (2018) 96:395–403. doi: 10.1139/cjpp-2017-0354

38. Morgante G, Massaro MG, Di Sabatino A, Cappelli V, De Leo V. Therapeutic approach for metabolic disorders and infertility in women with PCOS. Gynecol Endocrinol. (2018) 34:3–9. doi: 10.1080/10533590.2017.1376044

39. Le MT, Le VNS, Le DD, Nguyen V, Chen C, Cao NT. Exploration of the role of anti-Mullerian hormone and LH/FSH ratio in diagnosis of polycystic ovary syndrome. Clin Endocrinol. (2019) 90:579–85. doi: 10.1111/cen.13934

40. Yue CY, Lu KK, Li M, Zhang QL, Ying CM. Threshold value of anti-mullerian hormone for the diagnosis of polycystic ovary syndrome in Chinese women. PLoS ONE. (2018) 13:e0203129. doi: 10.1371/journal.pone.0203129

41. Young LR, Raatz SK, Thomas W, Redmon JB, Kurzer MS. Total dietary fat and omega-3 fatty acids have modest effects on urinary sex hormones in postmenopausal women. Nutr Metab. (2013) 10:36. doi: 10.1186/1743-7075-10-36

42. Eigeliene N, Elio T, Linhala M, Hurme S, Erikkola R, Harkonen P. Androgens inhibit the stimulatory action of 17beta-estradiol on normal human breast tissue in explant cultures. J Clin Endocrinol Metab. (2012) 97:E1166–27. doi: 10.1210/jc.2011-3228

43. Liu T, Cui YQ, Zhao H, Liu HB, Zhao SD, Gao Y, et al. High levels of testosterone inhibit ovarian follicle development by repressing the FSH receptor signaling pathway. J Huazhong Univ Sci Technolog Med Sci. (2015) 35:723–9. doi: 10.1016/s11596-015-1497-z

44. Zhu JL, Chen Z, Feng WJ, Long SL, Mo ZC. Sex hormone-binding globulin and polycystic ovary syndrome. Clin Chim Acta. (2019) 499, 142–9. doi: 10.1016/j.cca.2019.09.010

45. Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update. (2008) 14:367–78. doi: 10.1093/humupd/dmn015

46. Somboonporn W, Davis SR. Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev. (2004) 25:374–88. doi: 10.1210/er.2003-0016

Wang et al.
62. Kalgaonkar S, Almaruo RU, Gurusinghe D, Garamendi EM, Buchan W, Kim K, et al. Differential effects of walnuts vs almonds on improving metabolic and endocrine parameters in PCOS. *Eur J Clin Nutr*. (2011) 65:386–93. doi: 10.1038/ejcn.2010.266

63. Abruzzese GA, Heber MF, Ferreira SR, Velez LM, Reynoso R, Pignataro OP, et al. Prenatal hyperandrogenism induces alterations that affect liver lipid metabolism. *J Endocrinol*. (2016) 230:67–79. doi: 10.1530/JOE-15-0471

64. Ding L, Gao F, Zhang M, Yan W, Tang R, Zhang C, et al. Higher PDCD4 expression is associated with obesity, insulin resistance, lipid metabolism disorders, and granulosa cell apoptosis in polycystic ovary syndrome. *Fertil Steril*. (2016) 105:1330–7. doi: 10.1016/j.fertnstert.2016.01.020

65. Mohammadi E, Rafraf M. Benefits of omega-3 fatty acids supplementation on serum paraoxonase 1 activity and lipids ratios in polycystic ovary syndrome. *Health Promot Perspect*. (2012) 2:197–204. doi: 10.5681/hpp.2012.023

66. Vargas ML, Almaruo RU, Buchan W, Kim K, Karakas SE. Metabolic and endocrine effects of long-chain versus essential omega-3 polyunsaturated fatty acids in polycystic ovary syndrome. *Metabolism*. (2011) 60:1711–8. doi: 10.1016/j.metabol.2011.04.007

67. Wu JH, Cahill LE, Mozaffarian D. Effect of fish oil on circulating adiponectin: a systematic review and meta-analysis of randomized controlled trials. *J Clin Endocrinol Metab*. (2013) 98:2451–9. doi: 10.1210/jc.2012-13899

68. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. *Nat Med*. (2002) 8:1288–95. doi: 10.1038/nm788

69. Ojeda-Ojeda M, Murri M, Insenser M, Escobar-Morreale HF. Media tors between polycystic ovary syndrome and gut microbiota. *PLoS ONE*. (2013) 8:e153196. doi: 10.1371/journal.pone.0153196

70. Patel S. Polycystic ovary syndrome. (PCOS), an inflammatory, systemic, metabolic disease. *Curr Pharm Des*. (2013) 19:5775–91. doi: 10.2174/13816128131913030112

71. Jamilian M, Shojaei A, Samimi M, Afshar EE, Aghadavod E, Karamali M, et al. The effects of omega-3 and vitamin E co-supplementation on parameters of low-grade chronic inflammation in polycystic ovary syndrome. *Nephrol Dial Transplant*. (2015) 30:2566–74. doi: 10.1093/ndt/gfu283

72. Spencer M, Finlin BS, Unal R, Zhu B, Morris AJ, Shipp LR, et al. Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance. *Diabetes*. (2013) 62:1709–17. doi: 10.2337/db12-1042

73. Gonzalez F, Kirwan JP, Rote NS, Minium J, O’Leary VB. Glucose and lipopolysaccharide regulate proatherogenic cytokine release from mononuclear cells in polycystic ovary syndrome. *J Reprod Immunol*. (2014) 103:38–44. doi: 10.1016/j.jri.2014.01.001

74. Huang W, Guo HL, Deng X, Zhu TT, Xiong JF, Xu YH, et al. Short-chain fatty acids inhibit oxidative stress and inflammation in mesangial cells induced by high glucose and lipopolysaccharide. *Exp Clin Endocrinol Diabetes*. (2017) 125:98–105. doi: 10.1055/s-0042-121493

75. Park J, Kim M, Kang SG, Jannasch AH, Cooper B, Patterson J, et al. Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. *Mucosal Immunol*. (2015) 8:80–93. doi: 10.1038/mi.2014.44

76. Schilderink R, Verseijden C, Seppen J, Muncan V, van den Brink GR, Lambers TT, et al. The SCFA butyrate stimulates the epithelial production of retinoic acid via inhibition of epithelial HDAC. *Am J Physiol Gastrointest Liver Physiol*. (2016) 310:G1138–46. doi: 10.1152/ajpgi.00411.2015

77. Singh N, Gurav A, Sivaprakasan S, Brady E, Padia R, Shi H, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. *Immunity*. (2014) 40:128–39. doi: 10.1016/j.immuni.2013.12.007

78. Trompete A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom-Bru C, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. *Nat Med*. (2014) 20:156–66. doi: 10.1038/nm.3444

79. Wu W, Sun M, Chen F, Cao AT, Liu H, Zhao Y, et al. Microbiota metabolite short-chain fatty acid acetate promotes intestinal IgA response to microbiota which is mediated by GPR43. *Mucosal Immunol*. (2017) 10:946–56. doi: 10.1038/mi.2016.114

80. Bradley F, Burse K, Hasselrot K, Noel-Romas L, Introuni A, Wefer H, et al. The vaginal microbiome amplifies sex hormone-associated cyclic changes in cervicovaginal inflammation and epithelial barrier disruption. *Am J Reprod Immunol*. (2018) 80:e12863. doi: 10.1111/aji.12863

81. Heaps AC, Tyssen D, Srinovinski D, Bayigga L, Diaz D, Aldunate M, et al. Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition. *Mucosal Immunol*. (2017) 10:1480–90. doi: 10.1038/mi.2017.27

82. Aschbrenner K, Marchesi JR, Moges R, Sanglard D, Casali J, et al. The vaginal microbiome drives protein expression and metabolism in a rat model of menopause. *PLoS ONE*. (2016) 11:e0151396. doi: 10.1371/journal.pone.0151396

83. Yurdas G, Akdeveloglu Y. A new approach to polycystic ovary syndrome: the gut microbiota. *J Am Coll Nutr*. (2019) 39: 1–12. doi: 10.1080/07347769.2017.1657515

84. Zhang F, Ma T, Cui P, Tamadon A, He S, Huan C, et al. Diversity of the gut microbiota in dihydrotestosterone-induced PCOS rats and the pharmacological effects of diacerein-35, probiotics, and berberine. *Front Microbiol*. (2019) 10:175. doi: 10.3389/fmicb.2019.00175

85. Zacarias MF, Collado MC, Gomez-Gallego C, Finch H, Aittoniemi J, Isolauri E, et al. Pregestational overweight and obesity are associated with differences in gut microbiota composition and systemic inflammation in the third trimester. *PLoS ONE*. (2013) 8:e20305. doi: 10.1371/journal.pone.020305

86. Gonzalez F, Kirwan JP, Rote NS, Minium J, O’Leary VB. Glucose and lipopolysaccharide regulate proatherogenic cytokine release from mononuclear cells in polycystic ovary syndrome. *J Reprod Immunol*. (2014) 103:38–44. doi: 10.1016/j.jri.2014.01.001
99. Sher A, Rahman MA. Enterohepatic recycling of estrogen and its relevance with female fertility. *Arch Pharm Res.* (2000) 23:513–7. doi: 10.1007/BF02976582

100. Ferreira TM, Leonel AJ, Melo MA, Santos RR, Cara DC, Cardoso VN, et al. Oral supplementation of butyrate reduces mucositis and intestinal permeability associated with 5-Fluorouracil administration. *Lipids.* (2012) 47:669–78. doi: 10.1007/s11745-012-3680-3

101. Jin UH, Cheng Y, Park H, Davidson LA, Callaway ES, Chapkin RS, et al. Short chain fatty acids enhance aryl hydrocarbon (Ah) responsiveness in mouse colonocytes and caco-2 human colon cancer cells. *Sci Rep.* (2017) 7:10163. doi: 10.1038/s41598-017-10824-x

102. Zheng L, Kelly CJ, Battista KD, Schaefer R, Lanis JM, Alexeev EE, et al. Microbial-derived butyrate promotes epithelial barrier function through IL-10 receptor-dependent repression of claudin-2. *J Immunol.* (2017) 199:2976–84. doi: 10.4049/jimmunol.1700105

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2020 Wang, Sha, Li, Zhu, Wang, Li, Bao, Guo, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*